1. Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.
- Author
-
Zhang T, Meng C, He W, Xu T, Yang Y, Tu C, Zhang L, Sun X, Zhu C, Dang X, Wang K, Chen C, Yan X, Xu H, Huang L, Jiang E, Xia F, Zhou X, Zhou S, Zang W, Li X, Zhang J, Zheng J, Xin J, Huang B, Zhu G, Zhu J, and Liang J
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Surveys and Questionnaires, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Depression chemically induced, Patient Satisfaction, Quality of Life, Pyridines therapeutic use, Pyridines adverse effects, Cancer Survivors psychology, Patient Reported Outcome Measures, Neoplasms drug therapy, Sleep Initiation and Maintenance Disorders chemically induced
- Abstract
Background: Data on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with apatinib and severity of depression and insomnia., Methods: Patients with solid tumors who had received apatinib-based therapy for at least 5 years were invited to complete an online questionnaire. Characteristics of patients and treatment, knowledge of apatinib, satisfaction degree, and severity of depression and insomnia assessed by Patient Health Questionnaire-9 and Insomnia Severity Index were collected., Results: Between December 8, 2023 and March 1, 2024, a total of 436 patients completed the online questionnaire. Most patients were satisfied with the efficacy (96.6%) and safety (93.1%) of apatinib, were willing to continue apatinib treatment (99.5%), and would recommend apatinib to other patients (93.3%). Continuous apatinib treatment resulted in significant negative impact on daily life, work, or study in only two (0.5%) patients. Almost all patients currently had no or mild depression (97.0%) and insomnia (97.9%) problems. The most common patient-reported adverse events were hand-foot syndrome (21.3%) and hypertension (18.3%)., Conclusions: Our survey showed a high satisfaction degree with apatinib in long-term cancer survivors. Long-term apatinib treatment resulted in almost no negative impact on patient's quality of life., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF